{"entity":{"id":"piperacillin-tazobactam","kind":"drug","name":"Piperacillin with tazobactam","aka":["pip-taz","piperacillin-tazobactam","Tazocin"],"tldr":"Piperacillin with tazobactam is a broad-spectrum antibiotic drip. NICE recommends it as the first antibiotic for suspected neutropenic sepsis, a fever when white cells are low after chemotherapy.","summary":"The Zosyn label covers intra-abdominal infections, nosocomial and community-acquired pneumonia, skin and skin structure infections and female pelvic infections. NICE CG151: \"Offer beta lactam monotherapy with piperacillin with tazobactam as initial empiric antibiotic therapy to patients with suspected neutropenic sepsis who need intravenous treatment unless there are patient-specific or local microbiological contraindications.\" For neutropenic enterocolitis, AGIHO 2017 recommends piperacillin/tazobactam, imipenem/cilastatin or meropenem (BIII). The Zosyn NDA was approved on 22 October 1993.","status":"approved","asOf":"2026-11-11","wikipedia":"https://en.wikipedia.org/wiki/Piperacillin/tazobactam","links":[{"label":"US label (DailyMed): Zosyn","url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8db6bd91-2106-4bfd-8cc8-38aaf1e18d17"},{"label":"NICE CG151: Neutropenic sepsis, prevention and management in people with cancer, recommendations","url":"https://www.nice.org.uk/guidance/cg151/chapter/Recommendations"},{"label":"Schmidt-Hieber et al., Diagnosis and management of gastrointestinal complications in adult cancer patients: AGIHO guideline update (Ann Hematol 2018)","url":"https://doi.org/10.1007/s00277-017-3183-7"}],"tags":["supportive","generic","supportive-care-gaps-2026-11"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["febrile-neutropenia","neutropenic-enterocolitis-typhlitis"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo supportive care gap fill (DailyMed, openFDA, Drugs@FDA, emc SmPCs, NICE, ESMO, ASCO, MASCC, SITC, ASTCT, ITAC, Europe PMC)","editedOn":"2026-11-11"},"brand":"Zosyn / Tazocin","modality":"Penicillin-class antibacterial with a beta-lactamase inhibitor (intravenous)","supportive":true,"mechanism":"Piperacillin, a penicillin-class antibacterial, combined with tazobactam, a beta-lactamase inhibitor that protects it from bacterial enzymes.","approvals":[{"region":"US","year":1993,"indication":"Intra-abdominal infections, nosocomial and community-acquired pneumonia, skin and skin structure infections, female pelvic infections","note":"Year is the Zosyn NDA 050684 approval (Drugs@FDA)"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/piperacillin-tazobactam/","neighbours":{"term":[{"id":"febrile-neutropenia","kind":"term","name":"Febrile neutropenia","route":"/terms/febrile-neutropenia/"},{"id":"neutropenic-enterocolitis-typhlitis","kind":"term","name":"Neutropenic enterocolitis (typhlitis)","route":"/terms/neutropenic-enterocolitis-typhlitis/"}]}}